nodes	percent_of_prediction	percent_of_DWPC	metapath
Levomilnacipran—ABCB1—melanoma	0.382	1	CbGaD
Levomilnacipran—CYP3A4—Temozolomide—melanoma	0.102	0.284	CbGbCtD
Levomilnacipran—CYP2D6—Vemurafenib—melanoma	0.0882	0.245	CbGbCtD
Levomilnacipran—ABCB1—Dactinomycin—melanoma	0.0622	0.173	CbGbCtD
Levomilnacipran—CYP3A4—Vemurafenib—melanoma	0.0561	0.156	CbGbCtD
Levomilnacipran—ABCB1—Docetaxel—melanoma	0.0321	0.0892	CbGbCtD
Levomilnacipran—CYP3A4—Docetaxel—melanoma	0.0192	0.0534	CbGbCtD
Levomilnacipran—Pethidine—GRIN2A—melanoma	0.00349	0.864	CrCbGaD
Levomilnacipran—Dysgeusia—Vemurafenib—melanoma	0.00131	0.00714	CcSEcCtD
Levomilnacipran—Hot flush—Temozolomide—melanoma	0.00121	0.00662	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Temozolomide—melanoma	0.0012	0.00656	CcSEcCtD
Levomilnacipran—Thirst—Temozolomide—melanoma	0.00119	0.00651	CcSEcCtD
Levomilnacipran—Hyponatraemia—Carmustine—melanoma	0.00118	0.00643	CcSEcCtD
Levomilnacipran—Chest discomfort—Docetaxel—melanoma	0.00117	0.00641	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Dactinomycin—melanoma	0.00116	0.00632	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—melanoma	0.00113	0.00617	CcSEcCtD
Levomilnacipran—Infection—Vemurafenib—melanoma	0.00108	0.00592	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Carmustine—melanoma	0.00108	0.00591	CcSEcCtD
Levomilnacipran—Nervous system disorder—Vemurafenib—melanoma	0.00107	0.00584	CcSEcCtD
Levomilnacipran—Skin disorder—Vemurafenib—melanoma	0.00106	0.00578	CcSEcCtD
Levomilnacipran—Weight decreased—Bleomycin—melanoma	0.00105	0.00574	CcSEcCtD
Levomilnacipran—Dry skin—Temozolomide—melanoma	0.00104	0.00567	CcSEcCtD
Levomilnacipran—Blood pressure increased—Docetaxel—melanoma	0.00104	0.00567	CcSEcCtD
Levomilnacipran—Breast disorder—Temozolomide—melanoma	0.00103	0.00559	CcSEcCtD
Levomilnacipran—Hypotension—Vemurafenib—melanoma	0.00102	0.00556	CcSEcCtD
Levomilnacipran—Neutropenia—Dactinomycin—melanoma	0.00101	0.00553	CcSEcCtD
Levomilnacipran—Haematuria—Bleomycin—melanoma	0.000988	0.00539	CcSEcCtD
Levomilnacipran—Abdominal distension—Temozolomide—melanoma	0.000987	0.00539	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Dactinomycin—melanoma	0.000958	0.00523	CcSEcCtD
Levomilnacipran—Neutropenia—Carmustine—melanoma	0.000949	0.00518	CcSEcCtD
Levomilnacipran—Decreased appetite—Vemurafenib—melanoma	0.000948	0.00518	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Vemurafenib—melanoma	0.000942	0.00514	CcSEcCtD
Levomilnacipran—Fatigue—Vemurafenib—melanoma	0.000941	0.00513	CcSEcCtD
Levomilnacipran—Constipation—Vemurafenib—melanoma	0.000933	0.00509	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Bleomycin—melanoma	0.000926	0.00505	CcSEcCtD
Levomilnacipran—Neutropenia—Temozolomide—melanoma	0.000917	0.005	CcSEcCtD
Levomilnacipran—Dysuria—Temozolomide—melanoma	0.000917	0.005	CcSEcCtD
Levomilnacipran—Upper respiratory tract infection—Temozolomide—melanoma	0.000911	0.00497	CcSEcCtD
Levomilnacipran—Pollakiuria—Temozolomide—melanoma	0.000906	0.00494	CcSEcCtD
Levomilnacipran—Erectile dysfunction—Temozolomide—melanoma	0.000903	0.00493	CcSEcCtD
Levomilnacipran—Weight decreased—Temozolomide—melanoma	0.000887	0.00484	CcSEcCtD
Levomilnacipran—Urinary tract infection—Carmustine—melanoma	0.000879	0.0048	CcSEcCtD
Levomilnacipran—Hepatitis—Dactinomycin—melanoma	0.000868	0.00474	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Temozolomide—melanoma	0.000867	0.00473	CcSEcCtD
Levomilnacipran—Flushing—Bleomycin—melanoma	0.000863	0.00471	CcSEcCtD
Levomilnacipran—Body temperature increased—Vemurafenib—melanoma	0.000862	0.00471	CcSEcCtD
Levomilnacipran—Urinary tract infection—Temozolomide—melanoma	0.00085	0.00464	CcSEcCtD
Levomilnacipran—Chills—Bleomycin—melanoma	0.000835	0.00456	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Temozolomide—melanoma	0.000827	0.00451	CcSEcCtD
Levomilnacipran—Erythema multiforme—Dactinomycin—melanoma	0.00082	0.00448	CcSEcCtD
Levomilnacipran—Hallucination—Carmustine—melanoma	0.000808	0.00441	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Carmustine—melanoma	0.000808	0.00441	CcSEcCtD
Levomilnacipran—Hot flush—Docetaxel—melanoma	0.000806	0.0044	CcSEcCtD
Levomilnacipran—Flushing—Dactinomycin—melanoma	0.000805	0.00439	CcSEcCtD
Levomilnacipran—Hypersensitivity—Vemurafenib—melanoma	0.000804	0.00439	CcSEcCtD
Levomilnacipran—Oedema peripheral—Carmustine—melanoma	0.0008	0.00437	CcSEcCtD
Levomilnacipran—Menopausal symptoms—Docetaxel—melanoma	0.0008	0.00436	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Carmustine—melanoma	0.000798	0.00436	CcSEcCtD
Levomilnacipran—Hepatitis—Temozolomide—melanoma	0.000785	0.00428	CcSEcCtD
Levomilnacipran—Asthenia—Vemurafenib—melanoma	0.000783	0.00427	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Temozolomide—melanoma	0.000781	0.00426	CcSEcCtD
Levomilnacipran—Hallucination—Temozolomide—melanoma	0.000781	0.00426	CcSEcCtD
Levomilnacipran—Chills—Dactinomycin—melanoma	0.000779	0.00425	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Temozolomide—melanoma	0.000775	0.00423	CcSEcCtD
Levomilnacipran—Oedema peripheral—Temozolomide—melanoma	0.000773	0.00422	CcSEcCtD
Levomilnacipran—Pruritus—Vemurafenib—melanoma	0.000772	0.00421	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Temozolomide—melanoma	0.000771	0.00421	CcSEcCtD
Levomilnacipran—Urethral disorder—Temozolomide—melanoma	0.000769	0.0042	CcSEcCtD
Levomilnacipran—Eye disorder—Carmustine—melanoma	0.000759	0.00414	CcSEcCtD
Levomilnacipran—Hyponatraemia—Docetaxel—melanoma	0.000757	0.00413	CcSEcCtD
Levomilnacipran—Flushing—Carmustine—melanoma	0.000754	0.00411	CcSEcCtD
Levomilnacipran—Diarrhoea—Vemurafenib—melanoma	0.000746	0.00407	CcSEcCtD
Levomilnacipran—Migraine—Docetaxel—melanoma	0.000743	0.00405	CcSEcCtD
Levomilnacipran—Erythema multiforme—Temozolomide—melanoma	0.000742	0.00405	CcSEcCtD
Levomilnacipran—Eye disorder—Temozolomide—melanoma	0.000733	0.004	CcSEcCtD
Levomilnacipran—Cardiac disorder—Temozolomide—melanoma	0.000728	0.00398	CcSEcCtD
Levomilnacipran—Flushing—Temozolomide—melanoma	0.000728	0.00398	CcSEcCtD
Levomilnacipran—Leukopenia—Bleomycin—melanoma	0.000725	0.00396	CcSEcCtD
Levomilnacipran—Dizziness—Vemurafenib—melanoma	0.000721	0.00394	CcSEcCtD
Levomilnacipran—Angiopathy—Temozolomide—melanoma	0.000712	0.00389	CcSEcCtD
Levomilnacipran—Mental disorder—Carmustine—melanoma	0.000711	0.00388	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Temozolomide—melanoma	0.000707	0.00386	CcSEcCtD
Levomilnacipran—Malnutrition—Carmustine—melanoma	0.000707	0.00386	CcSEcCtD
Levomilnacipran—Chills—Temozolomide—melanoma	0.000704	0.00384	CcSEcCtD
Levomilnacipran—Liver function test abnormal—Docetaxel—melanoma	0.000696	0.0038	CcSEcCtD
Levomilnacipran—Vomiting—Vemurafenib—melanoma	0.000694	0.00379	CcSEcCtD
Levomilnacipran—Dry skin—Docetaxel—melanoma	0.000691	0.00377	CcSEcCtD
Levomilnacipran—Chest pain—Bleomycin—melanoma	0.00069	0.00376	CcSEcCtD
Levomilnacipran—Rash—Vemurafenib—melanoma	0.000688	0.00375	CcSEcCtD
Levomilnacipran—Mental disorder—Temozolomide—melanoma	0.000688	0.00375	CcSEcCtD
Levomilnacipran—Dermatitis—Vemurafenib—melanoma	0.000687	0.00375	CcSEcCtD
Levomilnacipran—Headache—Vemurafenib—melanoma	0.000683	0.00373	CcSEcCtD
Levomilnacipran—Malnutrition—Temozolomide—melanoma	0.000683	0.00373	CcSEcCtD
Levomilnacipran—Breast disorder—Docetaxel—melanoma	0.000682	0.00372	CcSEcCtD
Levomilnacipran—Leukopenia—Dactinomycin—melanoma	0.000676	0.00369	CcSEcCtD
Levomilnacipran—Dysgeusia—Temozolomide—melanoma	0.000669	0.00365	CcSEcCtD
Levomilnacipran—Vision blurred—Carmustine—melanoma	0.000666	0.00364	CcSEcCtD
Levomilnacipran—Tremor—Carmustine—melanoma	0.000662	0.00361	CcSEcCtD
Levomilnacipran—Infection—Bleomycin—melanoma	0.000657	0.00358	CcSEcCtD
Levomilnacipran—Agitation—Carmustine—melanoma	0.00065	0.00355	CcSEcCtD
Levomilnacipran—Nausea—Vemurafenib—melanoma	0.000648	0.00354	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Bleomycin—melanoma	0.000647	0.00353	CcSEcCtD
Levomilnacipran—Vision blurred—Temozolomide—melanoma	0.000644	0.00351	CcSEcCtD
Levomilnacipran—Tremor—Temozolomide—melanoma	0.00064	0.00349	CcSEcCtD
Levomilnacipran—Angina pectoris—Docetaxel—melanoma	0.000635	0.00347	CcSEcCtD
Levomilnacipran—Leukopenia—Carmustine—melanoma	0.000633	0.00345	CcSEcCtD
Levomilnacipran—Anorexia—Bleomycin—melanoma	0.00063	0.00344	CcSEcCtD
Levomilnacipran—Agitation—Temozolomide—melanoma	0.000628	0.00343	CcSEcCtD
Levomilnacipran—Hypotension—Bleomycin—melanoma	0.000618	0.00337	CcSEcCtD
Levomilnacipran—Convulsion—Carmustine—melanoma	0.000613	0.00334	CcSEcCtD
Levomilnacipran—Infection—Dactinomycin—melanoma	0.000612	0.00334	CcSEcCtD
Levomilnacipran—Leukopenia—Temozolomide—melanoma	0.000612	0.00334	CcSEcCtD
Levomilnacipran—Hypertension—Carmustine—melanoma	0.00061	0.00333	CcSEcCtD
Levomilnacipran—Neutropenia—Docetaxel—melanoma	0.00061	0.00333	CcSEcCtD
Levomilnacipran—Palpitations—Temozolomide—melanoma	0.000604	0.00329	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Dactinomycin—melanoma	0.000604	0.00329	CcSEcCtD
Levomilnacipran—Chest pain—Carmustine—melanoma	0.000602	0.00328	CcSEcCtD
Levomilnacipran—Anxiety—Carmustine—melanoma	0.0006	0.00327	CcSEcCtD
Levomilnacipran—Paraesthesia—Bleomycin—melanoma	0.000594	0.00324	CcSEcCtD
Levomilnacipran—Convulsion—Temozolomide—melanoma	0.000592	0.00323	CcSEcCtD
Levomilnacipran—Weight decreased—Docetaxel—melanoma	0.00059	0.00322	CcSEcCtD
Levomilnacipran—Hypertension—Temozolomide—melanoma	0.00059	0.00322	CcSEcCtD
Levomilnacipran—Dyspnoea—Bleomycin—melanoma	0.000589	0.00322	CcSEcCtD
Levomilnacipran—Anorexia—Dactinomycin—melanoma	0.000588	0.00321	CcSEcCtD
Levomilnacipran—Anxiety—Temozolomide—melanoma	0.00058	0.00316	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—melanoma	0.000578	0.00315	CcSEcCtD
Levomilnacipran—Stevens-Johnson syndrome—Docetaxel—melanoma	0.000576	0.00315	CcSEcCtD
Levomilnacipran—Decreased appetite—Bleomycin—melanoma	0.000575	0.00314	CcSEcCtD
Levomilnacipran—Infection—Carmustine—melanoma	0.000573	0.00313	CcSEcCtD
Levomilnacipran—Dry mouth—Temozolomide—melanoma	0.000569	0.0031	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Carmustine—melanoma	0.000565	0.00308	CcSEcCtD
Levomilnacipran—Tachycardia—Carmustine—melanoma	0.000563	0.00307	CcSEcCtD
Levomilnacipran—Infection—Temozolomide—melanoma	0.000554	0.00302	CcSEcCtD
Levomilnacipran—Pethidine—ALB—melanoma	0.000551	0.136	CrCbGaD
Levomilnacipran—Anorexia—Carmustine—melanoma	0.00055	0.003	CcSEcCtD
Levomilnacipran—Hepatobiliary disease—Docetaxel—melanoma	0.00055	0.003	CcSEcCtD
Levomilnacipran—Nervous system disorder—Temozolomide—melanoma	0.000547	0.00298	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Temozolomide—melanoma	0.000546	0.00298	CcSEcCtD
Levomilnacipran—Skin disorder—Temozolomide—melanoma	0.000542	0.00296	CcSEcCtD
Levomilnacipran—Hypotension—Carmustine—melanoma	0.000539	0.00294	CcSEcCtD
Levomilnacipran—Hyperhidrosis—Temozolomide—melanoma	0.000539	0.00294	CcSEcCtD
Levomilnacipran—Decreased appetite—Dactinomycin—melanoma	0.000536	0.00292	CcSEcCtD
Levomilnacipran—Fatigue—Dactinomycin—melanoma	0.000531	0.0029	CcSEcCtD
Levomilnacipran—Anorexia—Temozolomide—melanoma	0.000531	0.0029	CcSEcCtD
Levomilnacipran—Urticaria—Bleomycin—melanoma	0.000525	0.00287	CcSEcCtD
Levomilnacipran—Body temperature increased—Bleomycin—melanoma	0.000523	0.00285	CcSEcCtD
Levomilnacipran—Hepatitis—Docetaxel—melanoma	0.000522	0.00285	CcSEcCtD
Levomilnacipran—Insomnia—Carmustine—melanoma	0.000522	0.00285	CcSEcCtD
Levomilnacipran—Hypoaesthesia—Docetaxel—melanoma	0.000519	0.00283	CcSEcCtD
Levomilnacipran—Paraesthesia—Carmustine—melanoma	0.000518	0.00283	CcSEcCtD
Levomilnacipran—Urinary tract disorder—Docetaxel—melanoma	0.000515	0.00281	CcSEcCtD
Levomilnacipran—Dyspnoea—Carmustine—melanoma	0.000514	0.00281	CcSEcCtD
Levomilnacipran—Oedema peripheral—Docetaxel—melanoma	0.000514	0.00281	CcSEcCtD
Levomilnacipran—Somnolence—Carmustine—melanoma	0.000513	0.0028	CcSEcCtD
Levomilnacipran—Connective tissue disorder—Docetaxel—melanoma	0.000513	0.0028	CcSEcCtD
Levomilnacipran—Urethral disorder—Docetaxel—melanoma	0.000512	0.00279	CcSEcCtD
Levomilnacipran—Insomnia—Temozolomide—melanoma	0.000504	0.00275	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Dactinomycin—melanoma	0.000504	0.00275	CcSEcCtD
Levomilnacipran—Decreased appetite—Carmustine—melanoma	0.000502	0.00274	CcSEcCtD
Levomilnacipran—Paraesthesia—Temozolomide—melanoma	0.000501	0.00273	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Carmustine—melanoma	0.000498	0.00272	CcSEcCtD
Levomilnacipran—Dyspnoea—Temozolomide—melanoma	0.000497	0.00271	CcSEcCtD
Levomilnacipran—Somnolence—Temozolomide—melanoma	0.000496	0.00271	CcSEcCtD
Levomilnacipran—Erythema multiforme—Docetaxel—melanoma	0.000493	0.00269	CcSEcCtD
Levomilnacipran—Constipation—Carmustine—melanoma	0.000493	0.00269	CcSEcCtD
Levomilnacipran—Dyspepsia—Temozolomide—melanoma	0.000491	0.00268	CcSEcCtD
Levomilnacipran—Eye disorder—Docetaxel—melanoma	0.000488	0.00266	CcSEcCtD
Levomilnacipran—Abdominal pain—Dactinomycin—melanoma	0.000487	0.00266	CcSEcCtD
Levomilnacipran—Body temperature increased—Dactinomycin—melanoma	0.000487	0.00266	CcSEcCtD
Levomilnacipran—Hypersensitivity—Bleomycin—melanoma	0.000487	0.00266	CcSEcCtD
Levomilnacipran—Decreased appetite—Temozolomide—melanoma	0.000485	0.00265	CcSEcCtD
Levomilnacipran—Cardiac disorder—Docetaxel—melanoma	0.000484	0.00264	CcSEcCtD
Levomilnacipran—Flushing—Docetaxel—melanoma	0.000484	0.00264	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Temozolomide—melanoma	0.000481	0.00263	CcSEcCtD
Levomilnacipran—Fatigue—Temozolomide—melanoma	0.000481	0.00262	CcSEcCtD
Levomilnacipran—Constipation—Temozolomide—melanoma	0.000477	0.0026	CcSEcCtD
Levomilnacipran—Asthenia—Bleomycin—melanoma	0.000474	0.00259	CcSEcCtD
Levomilnacipran—Angiopathy—Docetaxel—melanoma	0.000474	0.00258	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Carmustine—melanoma	0.000472	0.00257	CcSEcCtD
Levomilnacipran—Mediastinal disorder—Docetaxel—melanoma	0.00047	0.00257	CcSEcCtD
Levomilnacipran—Chills—Docetaxel—melanoma	0.000468	0.00256	CcSEcCtD
Levomilnacipran—Pruritus—Bleomycin—melanoma	0.000468	0.00255	CcSEcCtD
Levomilnacipran—Mental disorder—Docetaxel—melanoma	0.000457	0.0025	CcSEcCtD
Levomilnacipran—Body temperature increased—Carmustine—melanoma	0.000456	0.00249	CcSEcCtD
Levomilnacipran—Abdominal pain—Carmustine—melanoma	0.000456	0.00249	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Temozolomide—melanoma	0.000456	0.00249	CcSEcCtD
Levomilnacipran—Malnutrition—Docetaxel—melanoma	0.000454	0.00248	CcSEcCtD
Levomilnacipran—Hypersensitivity—Dactinomycin—melanoma	0.000454	0.00248	CcSEcCtD
Levomilnacipran—Dysgeusia—Docetaxel—melanoma	0.000445	0.00243	CcSEcCtD
Levomilnacipran—Urticaria—Temozolomide—melanoma	0.000443	0.00242	CcSEcCtD
Levomilnacipran—Asthenia—Dactinomycin—melanoma	0.000442	0.00241	CcSEcCtD
Levomilnacipran—Abdominal pain—Temozolomide—melanoma	0.000441	0.00241	CcSEcCtD
Levomilnacipran—Body temperature increased—Temozolomide—melanoma	0.000441	0.00241	CcSEcCtD
Levomilnacipran—Hypersensitivity—Carmustine—melanoma	0.000425	0.00232	CcSEcCtD
Levomilnacipran—Diarrhoea—Dactinomycin—melanoma	0.000422	0.0023	CcSEcCtD
Levomilnacipran—Vomiting—Bleomycin—melanoma	0.00042	0.00229	CcSEcCtD
Levomilnacipran—Rash—Bleomycin—melanoma	0.000417	0.00227	CcSEcCtD
Levomilnacipran—Dermatitis—Bleomycin—melanoma	0.000416	0.00227	CcSEcCtD
Levomilnacipran—Asthenia—Carmustine—melanoma	0.000414	0.00226	CcSEcCtD
Levomilnacipran—Hypersensitivity—Temozolomide—melanoma	0.000411	0.00224	CcSEcCtD
Levomilnacipran—Syncope—Docetaxel—melanoma	0.000407	0.00222	CcSEcCtD
Levomilnacipran—Leukopenia—Docetaxel—melanoma	0.000407	0.00222	CcSEcCtD
Levomilnacipran—Palpitations—Docetaxel—melanoma	0.000401	0.00219	CcSEcCtD
Levomilnacipran—Asthenia—Temozolomide—melanoma	0.0004	0.00218	CcSEcCtD
Levomilnacipran—Loss of consciousness—Docetaxel—melanoma	0.000399	0.00218	CcSEcCtD
Levomilnacipran—Diarrhoea—Carmustine—melanoma	0.000395	0.00215	CcSEcCtD
Levomilnacipran—Pruritus—Temozolomide—melanoma	0.000394	0.00215	CcSEcCtD
Levomilnacipran—Convulsion—Docetaxel—melanoma	0.000394	0.00215	CcSEcCtD
Levomilnacipran—Nausea—Bleomycin—melanoma	0.000393	0.00214	CcSEcCtD
Levomilnacipran—Hypertension—Docetaxel—melanoma	0.000392	0.00214	CcSEcCtD
Levomilnacipran—Vomiting—Dactinomycin—melanoma	0.000392	0.00214	CcSEcCtD
Levomilnacipran—Rash—Dactinomycin—melanoma	0.000389	0.00212	CcSEcCtD
Levomilnacipran—Chest pain—Docetaxel—melanoma	0.000387	0.00211	CcSEcCtD
Levomilnacipran—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—melanoma	0.000384	0.0021	CcSEcCtD
Levomilnacipran—Dizziness—Carmustine—melanoma	0.000382	0.00208	CcSEcCtD
Levomilnacipran—Diarrhoea—Temozolomide—melanoma	0.000381	0.00208	CcSEcCtD
Levomilnacipran—Dry mouth—Docetaxel—melanoma	0.000378	0.00206	CcSEcCtD
Levomilnacipran—Dizziness—Temozolomide—melanoma	0.000369	0.00201	CcSEcCtD
Levomilnacipran—Infection—Docetaxel—melanoma	0.000368	0.00201	CcSEcCtD
Levomilnacipran—Vomiting—Carmustine—melanoma	0.000367	0.002	CcSEcCtD
Levomilnacipran—Nausea—Dactinomycin—melanoma	0.000366	0.002	CcSEcCtD
Levomilnacipran—Shock—Docetaxel—melanoma	0.000365	0.00199	CcSEcCtD
Levomilnacipran—Rash—Carmustine—melanoma	0.000364	0.00199	CcSEcCtD
Levomilnacipran—Nervous system disorder—Docetaxel—melanoma	0.000364	0.00198	CcSEcCtD
Levomilnacipran—Dermatitis—Carmustine—melanoma	0.000363	0.00198	CcSEcCtD
Levomilnacipran—Thrombocytopenia—Docetaxel—melanoma	0.000363	0.00198	CcSEcCtD
Levomilnacipran—Tachycardia—Docetaxel—melanoma	0.000362	0.00197	CcSEcCtD
Levomilnacipran—Headache—Carmustine—melanoma	0.000361	0.00197	CcSEcCtD
Levomilnacipran—Skin disorder—Docetaxel—melanoma	0.00036	0.00197	CcSEcCtD
Levomilnacipran—Vomiting—Temozolomide—melanoma	0.000355	0.00193	CcSEcCtD
Levomilnacipran—Anorexia—Docetaxel—melanoma	0.000353	0.00193	CcSEcCtD
Levomilnacipran—Rash—Temozolomide—melanoma	0.000352	0.00192	CcSEcCtD
Levomilnacipran—Dermatitis—Temozolomide—melanoma	0.000351	0.00192	CcSEcCtD
Levomilnacipran—Headache—Temozolomide—melanoma	0.000349	0.00191	CcSEcCtD
Levomilnacipran—Hypotension—Docetaxel—melanoma	0.000346	0.00189	CcSEcCtD
Levomilnacipran—Nausea—Carmustine—melanoma	0.000343	0.00187	CcSEcCtD
Levomilnacipran—Insomnia—Docetaxel—melanoma	0.000335	0.00183	CcSEcCtD
Levomilnacipran—Paraesthesia—Docetaxel—melanoma	0.000333	0.00182	CcSEcCtD
Levomilnacipran—Nausea—Temozolomide—melanoma	0.000331	0.00181	CcSEcCtD
Levomilnacipran—Dyspnoea—Docetaxel—melanoma	0.000331	0.0018	CcSEcCtD
Levomilnacipran—Somnolence—Docetaxel—melanoma	0.00033	0.0018	CcSEcCtD
Levomilnacipran—Dyspepsia—Docetaxel—melanoma	0.000326	0.00178	CcSEcCtD
Levomilnacipran—Decreased appetite—Docetaxel—melanoma	0.000322	0.00176	CcSEcCtD
Levomilnacipran—Gastrointestinal disorder—Docetaxel—melanoma	0.00032	0.00175	CcSEcCtD
Levomilnacipran—Fatigue—Docetaxel—melanoma	0.00032	0.00174	CcSEcCtD
Levomilnacipran—Constipation—Docetaxel—melanoma	0.000317	0.00173	CcSEcCtD
Levomilnacipran—Gastrointestinal pain—Docetaxel—melanoma	0.000303	0.00165	CcSEcCtD
Levomilnacipran—Abdominal pain—Docetaxel—melanoma	0.000293	0.0016	CcSEcCtD
Levomilnacipran—Body temperature increased—Docetaxel—melanoma	0.000293	0.0016	CcSEcCtD
Levomilnacipran—Hypersensitivity—Docetaxel—melanoma	0.000273	0.00149	CcSEcCtD
Levomilnacipran—Asthenia—Docetaxel—melanoma	0.000266	0.00145	CcSEcCtD
Levomilnacipran—Pruritus—Docetaxel—melanoma	0.000262	0.00143	CcSEcCtD
Levomilnacipran—Diarrhoea—Docetaxel—melanoma	0.000254	0.00138	CcSEcCtD
Levomilnacipran—Dizziness—Docetaxel—melanoma	0.000245	0.00134	CcSEcCtD
Levomilnacipran—Vomiting—Docetaxel—melanoma	0.000236	0.00129	CcSEcCtD
Levomilnacipran—Rash—Docetaxel—melanoma	0.000234	0.00128	CcSEcCtD
Levomilnacipran—Dermatitis—Docetaxel—melanoma	0.000234	0.00127	CcSEcCtD
Levomilnacipran—Headache—Docetaxel—melanoma	0.000232	0.00127	CcSEcCtD
Levomilnacipran—Nausea—Docetaxel—melanoma	0.00022	0.0012	CcSEcCtD
Levomilnacipran—CYP2J2—Metabolism—ABCB1—melanoma	4.54e-05	0.000644	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—melanoma	4.53e-05	0.000642	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ACER3—melanoma	4.41e-05	0.000624	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—TP53—melanoma	4.39e-05	0.000622	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—UGT2B10—melanoma	4.38e-05	0.000621	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G6—melanoma	4.33e-05	0.000613	CbGpPWpGaD
Levomilnacipran—CYP3A4—Biological oxidations—CYP1B1—melanoma	4.32e-05	0.000612	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDK2—melanoma	4.3e-05	0.00061	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—UGT2B10—melanoma	4.28e-05	0.000606	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metapathway biotransformation—CYP1B1—melanoma	4.26e-05	0.000604	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PRKCA—melanoma	4.18e-05	0.000592	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ERCC2—melanoma	4.14e-05	0.000587	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—melanoma	4.08e-05	0.000579	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HS3ST5—melanoma	4.07e-05	0.000577	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—melanoma	4.07e-05	0.000576	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—UGT2B10—melanoma	4.03e-05	0.000571	CbGpPWpGaD
Levomilnacipran—SLC6A4—Circadian rythm related genes—IL6—melanoma	4.01e-05	0.000569	CbGpPWpGaD
Levomilnacipran—ABCB1—Allograft Rejection—TNF—melanoma	3.98e-05	0.000564	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HS3ST5—melanoma	3.97e-05	0.000563	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—APC—melanoma	3.83e-05	0.000543	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EGF—melanoma	3.78e-05	0.000536	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HS3ST5—melanoma	3.75e-05	0.000531	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	3.67e-05	0.000521	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—melanoma	3.57e-05	0.000505	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—melanoma	3.51e-05	0.000497	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLCB4—melanoma	3.46e-05	0.00049	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	3.43e-05	0.000487	CbGpPWpGaD
Levomilnacipran—ABCB1—HIF-1-alpha transcription factor network—AKT1—melanoma	3.42e-05	0.000484	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—FASN—melanoma	3.39e-05	0.000481	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—melanoma	3.39e-05	0.00048	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP17A1—melanoma	3.28e-05	0.000465	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CG—melanoma	3.27e-05	0.000464	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC6A11—melanoma	3.25e-05	0.000461	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIP4K2A—melanoma	3.25e-05	0.000461	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—melanoma	3.22e-05	0.000457	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—MTAP—melanoma	3.16e-05	0.000448	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PPARG—melanoma	3.16e-05	0.000448	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	3.09e-05	0.000438	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLCB4—melanoma	3.09e-05	0.000437	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—melanoma	3.06e-05	0.000434	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—FASN—melanoma	3.03e-05	0.000429	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—melanoma	3.01e-05	0.000427	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLCB4—melanoma	3.01e-05	0.000427	CbGpPWpGaD
Levomilnacipran—SLC6A2—Transmembrane transport of small molecules—ALB—melanoma	3e-05	0.000425	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—melanoma	2.97e-05	0.000421	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—melanoma	2.91e-05	0.000412	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIP4K2A—melanoma	2.9e-05	0.000411	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC6A11—melanoma	2.9e-05	0.000411	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ACER3—melanoma	2.88e-05	0.000408	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CD—melanoma	2.88e-05	0.000408	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—ALB—melanoma	2.84e-05	0.000403	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLCB4—melanoma	2.84e-05	0.000402	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIP4K2A—melanoma	2.83e-05	0.000401	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC6A11—melanoma	2.83e-05	0.000401	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—MTAP—melanoma	2.82e-05	0.0004	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—LUM—melanoma	2.82e-05	0.0004	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PHGDH—melanoma	2.82e-05	0.0004	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—SLC5A5—melanoma	2.77e-05	0.000392	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—HPSE—melanoma	2.76e-05	0.000392	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—CYP1B1—melanoma	2.76e-05	0.000391	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—MTAP—melanoma	2.76e-05	0.000391	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—melanoma	2.75e-05	0.00039	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CUBN—melanoma	2.71e-05	0.000385	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—melanoma	2.7e-05	0.000382	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC6A11—melanoma	2.67e-05	0.000378	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIP4K2A—melanoma	2.67e-05	0.000378	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—UGT2B10—melanoma	2.63e-05	0.000373	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—melanoma	2.63e-05	0.000372	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CSPG4—melanoma	2.62e-05	0.000371	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SDHD—melanoma	2.62e-05	0.000371	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—BSG—melanoma	2.62e-05	0.000371	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—melanoma	2.6e-05	0.000369	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—MTAP—melanoma	2.6e-05	0.000368	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—melanoma	2.54e-05	0.00036	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GPAM—melanoma	2.54e-05	0.00036	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—melanoma	2.53e-05	0.000359	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—melanoma	2.52e-05	0.000358	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—LUM—melanoma	2.52e-05	0.000357	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PHGDH—melanoma	2.52e-05	0.000357	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CB—melanoma	2.51e-05	0.000356	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTGS2—melanoma	2.49e-05	0.000352	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—HPSE—melanoma	2.47e-05	0.00035	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PHGDH—melanoma	2.46e-05	0.000348	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—LUM—melanoma	2.46e-05	0.000348	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HS3ST5—melanoma	2.45e-05	0.000347	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CUBN—melanoma	2.42e-05	0.000343	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—HPSE—melanoma	2.41e-05	0.000341	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CUBN—melanoma	2.36e-05	0.000335	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—BSG—melanoma	2.34e-05	0.000332	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SDHD—melanoma	2.34e-05	0.000332	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CSPG4—melanoma	2.34e-05	0.000332	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PHGDH—melanoma	2.31e-05	0.000328	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—LUM—melanoma	2.31e-05	0.000328	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—melanoma	2.29e-05	0.000325	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—BSG—melanoma	2.28e-05	0.000324	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CSPG4—melanoma	2.28e-05	0.000324	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SDHD—melanoma	2.28e-05	0.000324	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—HPSE—melanoma	2.27e-05	0.000322	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GPAM—melanoma	2.27e-05	0.000321	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CUBN—melanoma	2.23e-05	0.000316	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GPAM—melanoma	2.21e-05	0.000313	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PTEN—melanoma	2.17e-05	0.000307	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—melanoma	2.17e-05	0.000307	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PLA2G6—melanoma	2.16e-05	0.000306	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SDHD—melanoma	2.15e-05	0.000305	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—BSG—melanoma	2.15e-05	0.000305	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CSPG4—melanoma	2.15e-05	0.000305	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—melanoma	2.11e-05	0.000299	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GPAM—melanoma	2.08e-05	0.000295	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK1—melanoma	2.06e-05	0.000292	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—melanoma	2.06e-05	0.000292	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—melanoma	1.96e-05	0.000278	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—melanoma	1.95e-05	0.000276	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—VCAN—melanoma	1.94e-05	0.000275	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PLA2G6—melanoma	1.93e-05	0.000273	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PLA2G6—melanoma	1.88e-05	0.000266	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLCB4—melanoma	1.86e-05	0.000263	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.83e-05	0.00026	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—melanoma	1.79e-05	0.000253	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PLA2G6—melanoma	1.77e-05	0.000251	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.77e-05	0.000251	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC6A11—melanoma	1.75e-05	0.000247	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIP4K2A—melanoma	1.75e-05	0.000247	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—VCAN—melanoma	1.73e-05	0.000245	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—melanoma	1.73e-05	0.000245	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—MTAP—melanoma	1.7e-05	0.000241	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—VCAN—melanoma	1.69e-05	0.000239	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CG—melanoma	1.64e-05	0.000232	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP17A1—melanoma	1.64e-05	0.000232	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.61e-05	0.000229	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—ALB—melanoma	1.59e-05	0.000226	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—VCAN—melanoma	1.59e-05	0.000226	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—melanoma	1.58e-05	0.000224	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GNA11—melanoma	1.54e-05	0.000219	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—PIK3CA—melanoma	1.53e-05	0.000217	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PHGDH—melanoma	1.51e-05	0.000214	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—LUM—melanoma	1.51e-05	0.000214	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—FASN—melanoma	1.51e-05	0.000214	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—SLC5A5—melanoma	1.49e-05	0.000211	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—HPSE—melanoma	1.48e-05	0.00021	CbGpPWpGaD
Levomilnacipran—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—melanoma	1.46e-05	0.000207	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP17A1—melanoma	1.46e-05	0.000207	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CUBN—melanoma	1.46e-05	0.000206	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CD—melanoma	1.44e-05	0.000204	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—GNAQ—melanoma	1.44e-05	0.000204	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CD44—melanoma	1.44e-05	0.000204	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP17A1—melanoma	1.42e-05	0.000202	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—ALB—melanoma	1.42e-05	0.000201	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—BSG—melanoma	1.41e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SDHD—melanoma	1.41e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CSPG4—melanoma	1.41e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.41e-05	0.000199	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.39e-05	0.000197	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GNA11—melanoma	1.38e-05	0.000195	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—CYP1B1—melanoma	1.38e-05	0.000195	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GPAM—melanoma	1.36e-05	0.000193	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—FASN—melanoma	1.35e-05	0.000191	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GNA11—melanoma	1.35e-05	0.000191	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP17A1—melanoma	1.34e-05	0.00019	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—SLC5A5—melanoma	1.33e-05	0.000188	CbGpPWpGaD
Levomilnacipran—ABCB1—Transmembrane transport of small molecules—ALB—melanoma	1.32e-05	0.000187	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—FASN—melanoma	1.32e-05	0.000187	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—SLC5A5—melanoma	1.3e-05	0.000184	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—GNAQ—melanoma	1.28e-05	0.000182	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CD44—melanoma	1.28e-05	0.000182	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GNA11—melanoma	1.27e-05	0.00018	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CB—melanoma	1.25e-05	0.000178	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—GNAQ—melanoma	1.25e-05	0.000177	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CD44—melanoma	1.25e-05	0.000177	CbGpPWpGaD
Levomilnacipran—CYP2J2—Metabolism—AKT1—melanoma	1.25e-05	0.000177	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—melanoma	1.24e-05	0.000176	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—FASN—melanoma	1.24e-05	0.000176	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—CYP1B1—melanoma	1.23e-05	0.000174	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—SLC5A5—melanoma	1.22e-05	0.000173	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.21e-05	0.000172	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—CYP1B1—melanoma	1.2e-05	0.00017	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—GNAQ—melanoma	1.18e-05	0.000167	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CD44—melanoma	1.18e-05	0.000167	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PLA2G6—melanoma	1.16e-05	0.000164	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ABCB1—melanoma	1.13e-05	0.000161	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—CYP1B1—melanoma	1.13e-05	0.00016	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—melanoma	1.08e-05	0.000154	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PRKCA—melanoma	1.04e-05	0.000148	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—VCAN—melanoma	1.04e-05	0.000147	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ERCC2—melanoma	1.03e-05	0.000147	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ABCB1—melanoma	1.01e-05	0.000143	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PRKCA—melanoma	9.31e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ABCB1—melanoma	9.31e-06	0.000132	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ERCC2—melanoma	9.24e-06	0.000131	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PRKCA—melanoma	9.09e-06	0.000129	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ERCC2—melanoma	9.01e-06	0.000128	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP17A1—melanoma	8.78e-06	0.000124	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	8.57e-06	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PRKCA—melanoma	8.56e-06	0.000121	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ERCC2—melanoma	8.49e-06	0.00012	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GNA11—melanoma	8.29e-06	0.000118	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CG—melanoma	8.17e-06	0.000116	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—FASN—melanoma	8.11e-06	0.000115	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—SLC5A5—melanoma	7.98e-06	0.000113	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PPARG—melanoma	7.89e-06	0.000112	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—GNAQ—melanoma	7.71e-06	0.000109	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CD44—melanoma	7.71e-06	0.000109	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—melanoma	7.65e-06	0.000108	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—CYP1B1—melanoma	7.39e-06	0.000105	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CG—melanoma	7.29e-06	0.000103	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CD—melanoma	7.18e-06	0.000102	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CG—melanoma	7.12e-06	0.000101	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—ALB—melanoma	7.09e-06	0.000101	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PPARG—melanoma	7.04e-06	9.98e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PPARG—melanoma	6.87e-06	9.74e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CG—melanoma	6.71e-06	9.51e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PPARG—melanoma	6.47e-06	9.18e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CD—melanoma	6.41e-06	9.09e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—ALB—melanoma	6.33e-06	8.97e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CB—melanoma	6.26e-06	8.88e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CD—melanoma	6.26e-06	8.87e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTGS2—melanoma	6.2e-06	8.79e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—ALB—melanoma	6.18e-06	8.76e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ABCB1—melanoma	6.08e-06	8.62e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CD—melanoma	5.9e-06	8.36e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—ALB—melanoma	5.82e-06	8.25e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PRKCA—melanoma	5.6e-06	7.94e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CB—melanoma	5.59e-06	7.92e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ERCC2—melanoma	5.55e-06	7.87e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTGS2—melanoma	5.54e-06	7.85e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CB—melanoma	5.45e-06	7.73e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PTEN—melanoma	5.41e-06	7.67e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTGS2—melanoma	5.41e-06	7.66e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CB—melanoma	5.14e-06	7.29e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTGS2—melanoma	5.09e-06	7.22e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PTEN—melanoma	4.83e-06	6.85e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PTEN—melanoma	4.71e-06	6.68e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PTEN—melanoma	4.44e-06	6.3e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CG—melanoma	4.39e-06	6.22e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PPARG—melanoma	4.23e-06	6e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CD—melanoma	3.86e-06	5.47e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—PIK3CA—melanoma	3.82e-06	5.41e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—ALB—melanoma	3.81e-06	5.4e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—PIK3CA—melanoma	3.41e-06	4.83e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CB—melanoma	3.36e-06	4.76e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTGS2—melanoma	3.33e-06	4.72e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—PIK3CA—melanoma	3.33e-06	4.71e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—PIK3CA—melanoma	3.13e-06	4.44e-05	CbGpPWpGaD
Levomilnacipran—CYP2C8—Metabolism—AKT1—melanoma	3.12e-06	4.42e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PTEN—melanoma	2.9e-06	4.12e-05	CbGpPWpGaD
Levomilnacipran—CYP2C19—Metabolism—AKT1—melanoma	2.78e-06	3.94e-05	CbGpPWpGaD
Levomilnacipran—ABCB1—Metabolism—AKT1—melanoma	2.72e-06	3.85e-05	CbGpPWpGaD
Levomilnacipran—CYP2D6—Metabolism—AKT1—melanoma	2.56e-06	3.63e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—PIK3CA—melanoma	2.05e-06	2.9e-05	CbGpPWpGaD
Levomilnacipran—CYP3A4—Metabolism—AKT1—melanoma	1.67e-06	2.37e-05	CbGpPWpGaD
